Suppr超能文献

分子伴侣在具有突变及MDM2上调的癌细胞获得化学抗性中的作用

Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated and MDM2 up-regulation.

作者信息

Tracz-Gaszewska Zuzanna, Klimczak Marta, Biecek Przemyslaw, Herok Marcin, Kosinski Marcin, Olszewski Maciej B, Czerwińska Patrycja, Wiech Milena, Wiznerowicz Maciej, Zylicz Alicja, Zylicz Maciej, Wawrzynow Bartosz

机构信息

International Institute of Molecular and Cell Biology, Warsaw, Poland.

Institute of Biochemistry and Biophysics, PAS, Warsaw, Poland.

出版信息

Oncotarget. 2017 Jun 30;8(47):82123-82143. doi: 10.18632/oncotarget.18899. eCollection 2017 Oct 10.

Abstract

Utilizing the TCGA PANCAN12 dataset we discovered that cancer patients with mutations in tumor suppressor and overexpression of oncogene exhibited decreased survival post treatment. Interestingly, in the case of breast cancer patients, this phenomenon correlated with high expression level of several molecular chaperones belonging to the HSPA, DNAJB and HSPC families. To verify the hypothesis that such a genetic background may promote chaperone-mediated chemoresistance, we employed breast and lung cancer cell lines that constitutively overexpressed heat shock proteins and have shown that HSPA1A/HSP70 and DNAJB1/HSP40 facilitated the binding of mutated p53 to the TAp73α protein. This chaperone-mediated mutated p53-TAp73α complex induced chemoresistance to DNA damaging reagents, like Cisplatin, Doxorubicin, Etoposide or Camptothecin. Importantly, when the oncogene was overexpressed, heat shock proteins were displaced and a stable multiprotein complex comprising of mutated p53-TAp73α-MDM2 was formed, additionally amplifying cancer cells chemoresistance. Our findings demonstrate that molecular chaperones aid cancer cells in surviving the cytotoxic effect of chemotherapeutics and may have therapeutic implications.

摘要

利用TCGA PANCAN12数据集,我们发现肿瘤抑制基因发生突变且癌基因过表达的癌症患者在治疗后生存率降低。有趣的是,在乳腺癌患者中,这种现象与属于HSPA、DNAJB和HSPC家族的几种分子伴侣的高表达水平相关。为了验证这种遗传背景可能促进伴侣介导的化疗耐药性这一假设,我们使用了组成性过表达热休克蛋白的乳腺癌和肺癌细胞系,并表明HSPA1A/HSP70和DNAJB1/HSP40促进了突变型p53与TAp73α蛋白的结合。这种伴侣介导的突变型p53-TAp73α复合物诱导了对DNA损伤试剂(如顺铂、阿霉素、依托泊苷或喜树碱)的化疗耐药性。重要的是,当癌基因过表达时,热休克蛋白被取代,形成了由突变型p53-TAp73α-MDM2组成的稳定多蛋白复合物,进一步增强了癌细胞的化疗耐药性。我们的研究结果表明,分子伴侣有助于癌细胞在化疗药物的细胞毒性作用下存活,可能具有治疗意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8675/5669876/47480ed6c422/oncotarget-08-82123-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验